AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year

• AtriCure posted Q2 revenue of USD 153.6 million, up 12.8% year over year, swinging to net income of USD 9 million.
• Operating income turned positive at USD 9.7 million; gross margin widened 2.69 percentage points to 77.2%.
• Pain management revenue climbed 27.8% to USD 27.1 million, while minimally invasive ablation fell 23.1% to USD 6 million.
• Appendage management revenue rose 14.4% to USD 51.6 million; open ablation increased 12.1% to USD 40.9 million.
• Received EU MDR CE mark for AtriClip FLEX-Mini and AtriClip PRO-Mini in April; expects to launch both in Europe later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AtriCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001323885-26-000035), on July 27, 2026, and is solely responsible for the information contained therein.